Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

BACKGROUND AND AIMS: Treatment of hepatitis C virus (HCV) changed dramatically with the introduction of oral direct-acting antiviral drugs due to their high antiviral potency and safety profile. Sofosbuvir plus daclatasvir combination therapy was extensively investigated in HCV genotypes 1, 2, and 3...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Infect Drug Resist
Главные авторы: Ahmed, Ossama A, Elsebaey, Mohamed A, Fouad, Mohamed Hassan A, Elashry, Heba, Elshafie, Ahmed I, Elhadidy, Ahmed A, Esheba, Noha E, Elnaggar, Mohammed H, Soliman, Shaimaa, Abd-Elsalam, Sherief
Формат: Artigo
Язык:Inglês
Опубликовано: SAGE Publications 2018
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5878661/
https://ncbi.nlm.nih.gov/pubmed/29628768
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S160593
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы